A Frier Levitt attorney is featured in an EndPoints News article, “Hims’ Push into Compounded GLP-1 Drugs Risks Scrutiny from Novo Nordisk” by Ngai Yeung. The article sheds light on the digital health company Hims & Hers decision to begin prescribing a more affordable, compounded version of a popular GLP-1 weight loss drug. This move could attract scrutiny from pharmaceutical companies.
Read the article here: https://endpts.com/hims-push-into-compounded-glp-1-drugs-risks-scrutiny-from-novo-nordisk/
